USA temporarily stops Janssen vaccine after six thrombosed cases

The United States takes a break for the use of the Janssen vaccine after six reports of a rare form of thrombosis. This is done on the advice of the CDC, the American counterpart of the RIVM, and drug watchdog FDA. The signs of disease reported are strongly reminiscent of the rare side effect of the Astra Zeneca vaccine.

The two departments are investigating the six thrombosed cases that occurred in women between 18 and 48 years of age. One of the women died, another is in the hospital. Almost seven million Americans have now been vaccinated with the Janssen vaccine, with one shot sufficient for immunity against the coronavirus.

According to the health authorities, the possible adverse reaction, which has not been established, is extremely rare. They emphasize that they do not want to take any risks.

Until the research results are known, a break is taken. The federal government will stop vaccinating with the Janssen vaccine and it is expected that states and other vaccine providers will follow.

Also in Europe reports

The Netherlands has ordered over 11 million doses of the Janssen vaccine, partly developed in Leiden. Yesterday the first batch of the drug arrived in the Netherlands. Initially, the hospital staff are mainly vaccinated with it.

In Europe, a number of reports of thrombotic symptoms have been reported after receiving a Janssen prick, but it remains to be determined whether this is actually an adverse reaction.

Known update of AstraZeneca

There are also at least eight reports of a rare combination of thrombosis and a reduced platelet count in the Netherlands after receiving the AstraZeneca vaccine. The Cabinet then decided to administer this resource only to those over 60, to the incomprehension of general practitioners, among others.

The European Medicines Agency has considered that the benefits of the vaccine outweigh its side effects. The risk of the very rare side effect of the Astrazeneca vaccine is probably less than 1 in 100,000.